This study used data from the Longitudinal Prescription Database, which includes 92% of retail prescriptions in the US, to calculate rates of initiation of buprenorphine treatment and treatment retention (180 days or more of continuous treatment).  Researchers were looking for increased buprenorphine use because of relaxed waiver requirements in April 2021 and eased pandemic restrictions allowing better access to health care.

See what they found: https://jamanetwork.com/journals/jama/article-abstract/2804078